Tumor cells have been shown to grow resistant to single-agent MEK inhibition, resulting in either a compensatory upregulation of RAS/RAF/MEK/ERK signaling or activity of other pathways such as the mTOR pathway or HGF/MET pathway [147]. The gene discussed is MAP2K7; the disease is neoplasm.